Alnylam Pharmaceuticals (ALNY) Gets $25M Approval Payment, Up to 15% Royalties
Alnylam Pharmaceuticals (ALNY) received FDA approval for Livsayis, a treatment for gMG. The company will get a $25M payment and up to 15% royalties on global sales. Regeneron developed the drug after taking over in 2024. Alnylam expects recurring revenue from royalties, but no sales data was provided.
How this was made

The 30-second read
Why it matters
The approval is a regulatory milestone that can translate into cash (approval payment) and future royalty economics (tiered up to 15% of global net sales), but the article lacks sales volumes, launch timing, and tier thresholds.
Market read
Traders can update expectations for Alnylam’s partnered-program cash flows and royalty potential based on a newly disclosed regulatory approval milestone.
What to watch
The article does not provide prior-period comparisons or commercialization timing details, so investors may need follow-on disclosures on launch uptake and royalty reporting mechanics.
Background
The piece attributes the FDA approval of Livsayis to Alnylam’s partnered RNAi platform, noting Regeneron’s development role after taking sole responsibility in 2024.
Ticker impact
FDA approved Livsayis for adults with anti-AChR antibody-positive gMG, with Alnylam set to receive a $25M approval payment and up to 15% royalties.
Likely positive bias as investors price in additional royalty revenue potential from the newly approved therapy.
The article discloses a specific FDA approval and quantifies the approval payment plus royalty ceiling, which can change expectations for future royalty streams even without sales guidance or near-term revenue numbers.
Market effects
Reinforces the value of RNAi platform partnerships and can modestly support sentiment toward biotech royalty models tied to regulatory milestones.
Limited, primarily US biotech sentiment given FDA approval framing.
Moderate, since royalties are described as on global net sales, but no geography-specific launch details are provided.
Counterpoint
Without any disclosed sales trajectory, the royalty upside may be less immediate than the headline implies, limiting near-term earnings impact.
Key entities
- companyAlnylam Pharmaceuticals
Receives a $25M approval payment and is eligible for tiered royalties up to 15% on global net sales following FDA approval of Livsayis.
- drugLivsayis
FDA-approved therapy for adults with anti-AChR antibody-positive gMG, triggering the milestone economics for Alnylam.
- regulatorFDA
Approved Livsayis for the specified gMG patient population.

